SCHEMBL250575

SCHEMBL250575

O=S(=O)(Oc1cccc2cccnc12)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 3/20 1.00
METAP1 P53582 3/20 1.00
GLRA3 O75311 2/20 0.58
GLRB P48167 1/20 0.58
LMNA P02545 4/20 0.52
SLC40A1 Q9NP59 3/20 0.52
G6PD P11413 1/20 0.52
NFKBIA P25963 1/20 0.52
AGTR1 P30556 1/20 0.52
GLO1 Q04760 1/20 0.52
PAX8 Q06710 1/20 0.52
ATM Q13315 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
RAB9A P51151 2/20 0.51
MAPT P10636 1/20 0.51
KDM4E B2RXH2 1/20 0.50
HSP90AA1 P07900 1/20 0.49
ALDH1A1 P00352 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30309411 1.00 METAP2 (1.00) METAP2METAP1GLRA3GLRBLMNA
SCHEMBL28581571 0.88 METAP2 (0.78) METAP2METAP1GLRA3GLRBLMNA
SCHEMBL27974930 0.87 METAP2 (0.76) METAP2METAP1GLRA3GLRBLMNA
SCHEMBL3263766 0.87 METAP2 (0.76) METAP2METAP1GLRA3GLRBLMNA
SCHEMBL18419283 0.82 METAP2 (0.69) METAP2METAP1LMNASLC40A1AGTR1
SCHEMBL7257985 0.82 METAP2 (0.69) METAP2METAP1GLRA3GLRBLMNA
SCHEMBL21306590 0.79 METAP2 (0.65) METAP2METAP1LMNASLC40A1AGTR1
SCHEMBL19568045 0.79 METAP2 (0.65) METAP2METAP1GLRA3GLRBLMNA
SCHEMBL10815877 0.79 METAP2 (0.65) METAP2METAP1GLRA3GLRBLMNA
SCHEMBL1831164 0.79 METAP2 (0.65) METAP2METAP1GLRA3GLRBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250354931-A1 SPATIAL TARGETING OF ANALYTES 10X GENOMICS INC (US) 2025-11-20 US claimed
US-12399123-B1 Spatial targeting of analytes 10X GENOMICS, INC. (US) 2025-08-26 US claimed
US-20240197884-A1 COMPOSITIONS AND METHODS FOR TARGETED TUMOR IMMUNOTHERAPY DANA FARBER CANCER INST INC (US) 2024-06-20 US claimed
US-20200306376-A1 COMPOSITIONS AND METHODS FOR TARGETED TUMOR IMMUNOTHERAPY DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-10-01 US claimed
CN-110545847-A Compositions and methods for targeted immunotherapy of tumors DANA FARBER CANCER INST INC 2019-12-06 CN claimed
WO-2018200713-A1 COMPOSITIONS AND METHODS FOR TARGETED TUMOR IMMUNOTHERAPY DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-11-01 WO claimed
US-20160297820-A1 DIMERIZER COMPOUND AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2016-10-13 US claimed
WO-2015034440-A2 A Dimerizer Compound AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-03-12 WO claimed
EP-2649102-A1 POLYMERS FUNCTIONALIZED WITH OXIME COMPOUNDS CONTAINING AN ACYL GROUP Bridgestone Corporation (JP) 2013-10-16 EP claimed
WO-2012078962-A1 POLYMERS FUNCTIONALIZED WITH OXIME COMPOUNDS CONTAINING AN ACYL GROUP BRIDGESTONE CORPORATION (JP) 2012-06-14 WO claimed
US-20120077941-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2012-03-29 US claimed
US-8088868-B2 oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis BRIDGESTONE CORPORATION (JP) 2012-01-03 US claimed
US-20080146745-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2008-06-19 US claimed
US-12630859-B2 Method for transcriptome analysis of single cells HIFIBIO SAS (FR) 2026-05-19 US disclosed
US-20260132451-A1 RESOLVING SPATIAL ARRAYS BY PROXIMITY-BASED DECONVOLUTION 10X GENOMICS, INC. (US) 2026-05-14 US disclosed
US-12618832-B2 Identification of cognate pairs of ligands and receptors PARIS SCIENCES ET LETTRES (FR) 2026-05-05 US disclosed
WO-2012078962-A1 POLYMERS FUNCTIONALIZED WITH OXIME COMPOUNDS CONTAINING AN ACYL GROUP BRIDGESTONE CORPORATION (JP) 2012-06-14 WO disclosed
US-20120077941-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2012-03-29 US disclosed
US-8088868-B2 oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis BRIDGESTONE CORPORATION (JP) 2012-01-03 US disclosed
US-20080146745-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297820-A1 DIMERIZER COMPOUND BID, BMP4, GCG METAP2 68/4885METAP1 76/4885GLRA3 2525/4885
US-20200306376-A1 COMPOSITIONS AND METHODS FOR TARGETED TUMOR IMMUNOTHERAPY CD47, CD274, CD74 METAP2 1424/4885METAP1 1048/4885GLRA3 3226/4885
US-12630859-B2 Method for transcriptome analysis of single cells RNGTT, METTL16, ELL METAP2 3322/4885METAP1 2339/4885GLRA3 4680/4885
US-12618832-B2 Identification of cognate pairs of ligands and receptors CD14, MSR1, GPR174 METAP2 1474/4885METAP1 992/4885GLRA3 253/4885
US-20260132451-A1 RESOLVING SPATIAL ARRAYS BY PROXIMITY-BASED DECONVOLUTION RNGTT, ADAR, CPSF1 METAP2 2467/4885METAP1 3192/4885GLRA3 4363/4885
US-20240197884-A1 COMPOSITIONS AND METHODS FOR TARGETED TUMOR IMMUNOTHERAPY CD47, CD274, CD2 METAP2 1702/4885METAP1 1427/4885GLRA3 3291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.